Contributions
Abstract: EP1286
Type: ePoster
Abstract Category: Clinical aspects of MS - 1 Diagnosis and differential diagnosis
The oligodendrocyte myelin glycoprotein (MOG) is a potential target of cellular and humoral response in the inflammatory process of demyelinating diseases of the Central Nervous System (DDs). Anti-Aquaporin 4 receptor antibodies (AQP4) are sensitive serologic markers of autoimmunity in Neuromyelitis Optica (NMO) and NMO spectrum disorders. Both can be used for diagnosis and differential diagnosis of these syndromes and can be performed by two laboratory methods, indirect immunofluorescence (AQP4) and live cell based assays for AQP4 and MOG.The frequency of antibody positivity against AQP4 and MOG- using the live cell based assays for AQP4-Abs and antibodies against MOG was investigated in patients with DDs treated in 2016 at a reference center in Rio de Janeiro/Brazil.A total of 67 patients were evaluated: Multiple Sclerosis (MS): 7 patients; Acute disseminated encephalomyelitis (ADEM): 3 patients; Optic-spinal Multiple sclerosis (OS-MS): 9 patients; NMO: 26 patients, Recurrent bilateral optic neuritis (RON): 16 patients and Transverse Myelitis (TM): 6 patients. 21 patients were seropositive for AQP4 and 3 for MOG. According to the diagnosis distribution, positive for AQP4: NMO: 50% (13/26); RON: 25% (4/16); TM: 33% (2/6); other cases were seronegative. Positive for MOG was observed in 2 patients with RON and 1 patient with TM after infection by Zika virus.Regarding NMO patients, the frequency of anti-AQP4 positivity was 50%, comparable to the results obtained by indirect immunofluorescence method already described in the literature, as well as in cases of RON (25% positivity) and TM (33 %). Regarding anti-MOG screening, it was not observed in most patients, except in 2 NOR patients (12.5%) and one case of post-infectious myelitis by the Zika virus, the first described in the literature so far. There was no simultaneous positivity between AQP4 and anti-MOG in this series.
Disclosure:
Vanderson Neri: nothing to disclose
Alexandre Lopes: nothing to disclose
Elizabeth Batista: nothing to disclose
Solange Camargo: nothing to disclose
Ana Carolina Araujo: nothing to disclose
Marcos Alvarenga: nothing to disclose
Cleonice Bento: nothing to disclose
Priscila Barros: nothing to disclose
Claudia Vasconcelos: nothing to disclose
Regina Alvarenga: nothing to disclose
Abstract: EP1286
Type: ePoster
Abstract Category: Clinical aspects of MS - 1 Diagnosis and differential diagnosis
The oligodendrocyte myelin glycoprotein (MOG) is a potential target of cellular and humoral response in the inflammatory process of demyelinating diseases of the Central Nervous System (DDs). Anti-Aquaporin 4 receptor antibodies (AQP4) are sensitive serologic markers of autoimmunity in Neuromyelitis Optica (NMO) and NMO spectrum disorders. Both can be used for diagnosis and differential diagnosis of these syndromes and can be performed by two laboratory methods, indirect immunofluorescence (AQP4) and live cell based assays for AQP4 and MOG.The frequency of antibody positivity against AQP4 and MOG- using the live cell based assays for AQP4-Abs and antibodies against MOG was investigated in patients with DDs treated in 2016 at a reference center in Rio de Janeiro/Brazil.A total of 67 patients were evaluated: Multiple Sclerosis (MS): 7 patients; Acute disseminated encephalomyelitis (ADEM): 3 patients; Optic-spinal Multiple sclerosis (OS-MS): 9 patients; NMO: 26 patients, Recurrent bilateral optic neuritis (RON): 16 patients and Transverse Myelitis (TM): 6 patients. 21 patients were seropositive for AQP4 and 3 for MOG. According to the diagnosis distribution, positive for AQP4: NMO: 50% (13/26); RON: 25% (4/16); TM: 33% (2/6); other cases were seronegative. Positive for MOG was observed in 2 patients with RON and 1 patient with TM after infection by Zika virus.Regarding NMO patients, the frequency of anti-AQP4 positivity was 50%, comparable to the results obtained by indirect immunofluorescence method already described in the literature, as well as in cases of RON (25% positivity) and TM (33 %). Regarding anti-MOG screening, it was not observed in most patients, except in 2 NOR patients (12.5%) and one case of post-infectious myelitis by the Zika virus, the first described in the literature so far. There was no simultaneous positivity between AQP4 and anti-MOG in this series.
Disclosure:
Vanderson Neri: nothing to disclose
Alexandre Lopes: nothing to disclose
Elizabeth Batista: nothing to disclose
Solange Camargo: nothing to disclose
Ana Carolina Araujo: nothing to disclose
Marcos Alvarenga: nothing to disclose
Cleonice Bento: nothing to disclose
Priscila Barros: nothing to disclose
Claudia Vasconcelos: nothing to disclose
Regina Alvarenga: nothing to disclose